CVinter > CVintra! [Power / Sample Size]

posted by stat_be – 2007-10-03 09:35 (6840 d 09:28 ago) – Posting: # 1151
Views: 12,974

Dear HS, thanks

❝ So you are talking about a cross-over design.


Yes. It is a cross-over design for pilot be of 12 subjects.

❝ Yes, this is the rule. In a cross-over design the PK responses within a particular subject are compared (between occasions).

❝ I hardly can imaginge a situation where variability between subjects (i.e., Brown vs Blair) is lower than within a subjecti.e., Brown on day 1 vs Brown on day 2). Although theoretical possible from a statistical point of view, such a behaviour is counterintuitive, and IMHO not a single case is described in the literature.

❝ BTW, the expectation of CVintra < CVinter leads to the general preference of cross-over designs over parallel designs in BE studies.


Please find below data for Tmax of a drug XXX and suggest. I have used proc glm for this and here MSE_Sub(seq) is less than MSE_residual so inter subject CV% can not be calculated. This is practical data obtained. Please let me know that which kind of conclusion should be made on the basis of this data. Same thing happened in the data of Cmax where %CV_inter < %CV_intra.

Sub Seq   Tmax_P-I  Tmax_P-II
 1   BA      3.50      2.50
 2   BA      1.50      3.00
 3   AB      2.50      5.00
 4   AB      3.50      2.50
 5   BA      5.00      2.50
 6   AB      2.50      2.50
 7   AB      2.50      2.50
 8   BA      3.00      4.50
 9   BA      4.00      4.00
10   AB      1.50      2.00
11   BA      2.50      3.00
12   AB      3.00      3.00


Please discuss as so many of new comers in the feild might be facing this kind of problem.

Thanks in advance.

Stat_BE

--
Edit: Tabs removed from table; original quotes restored (see here). [HS]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
140 visitors (0 registered, 140 guests [including 32 identified bots]).
Forum time: 19:04 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5